These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21726160)

  • 1. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
    Foss FM
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
    Shimanovsky A; Dasanu CA
    Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
    Parker T; Barbarotta L; Foss F
    Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
    Hui J; Przespo E; Elefante A
    J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pralatrexate (Folotyn).
    Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
    Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
    Molina JR
    IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
    Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
    Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pralatrexate: basic understanding and clinical development.
    Zain J; O'Connor O
    Expert Opin Pharmacother; 2010 Jul; 11(10):1705-14. PubMed ID: 20509772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
    O'Connor OA
    Curr Opin Oncol; 2006 Nov; 18(6):591-7. PubMed ID: 16988580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralatrexate, a new hope for aggressive T-cell lymphomas?
    Rueda A; Casanova M; Quero C; Medina-Pérez A
    Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pralatrexate - from bench to bedside.
    Zain JM; Marchi E
    Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
    Malik SM; Liu K; Qiang X; Sridhara R; Tang S; McGuinn WD; Verbois SL; Marathe A; Williams GM; Bullock J; Tornoe C; Lin SC; Ocheltree T; Vialpando M; Kacuba A; Justice R; Pazdur R
    Clin Cancer Res; 2010 Oct; 16(20):4921-7. PubMed ID: 20739433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
    Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
    J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
    Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA
    Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Jennifer C Z; Sara Mohamed J; Salma A; Francine F
    Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
    O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
    J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
    O'Connor OA; Horwitz S; Hamlin P; Portlock C; Moskowitz CH; Sarasohn D; Neylon E; Mastrella J; Hamelers R; Macgregor-Cortelli B; Patterson M; Seshan VE; Sirotnak F; Fleisher M; Mould DR; Saunders M; Zelenetz AD
    J Clin Oncol; 2009 Sep; 27(26):4357-64. PubMed ID: 19652067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
    Kelly KR; Gabrail N; Weitman S; Sarantopoulos J; Olszanski AJ; Edenfield W; Venitz J; Reddy G; Yang A; Hasal SJ; Lockhart AC
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):929-939. PubMed ID: 27638045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.